Seroprevalence of SARS-CoV-2 in Patients with Multiple Sclerosis under Disease-Modifying Therapies: A Multi-Centre Study

Seroprevalence of SARS-CoV-2 in Patients with Multiple Sclerosis under Disease-Modifying Therapies: A Multi-Centre Study

Background: The EMCOVID project conducted a multi-centre cohort study to investigate the impact of COVID-19 on patients with Multiple Sclerosis (pwMS) receiving disease-modifying therapies (DMTs). The study aimed to evaluate the seroprevalence and persistence of SARS-CoV-2 antibodies in MS patients...

Full description

Bibliographic Details
Main Authors: Agustín Sancho-Saldaña, Anna Gil-Sánchez, Cristina González-Mingot, Silvia Peralta, Maria Jose Solana, Pascual Torres, Alba Juanes, Laura Quibus, Emilio Ruiz, Eduardo Sanpedro, Bibiana Quirant-Sánchez, Eva Martínez-Cáceres, Cristina Ramo Tello, Silvia Presas-Rodríguez, Sebatián García Rubio, Beatriz Pardiñas Baron, Lluís Ramió-Torrentà, Javier Sotoca, Inés González-Suárez, Sara Eichau, José M. Prieto-González, Maria Rosario Blasco Quilez, Julia Sabín-Muñoz, Antonio José Sánchez-López, Gloria Llorens Calatayud, Carmen Calles, Ángel Pérez Sempere, Moises Garcés, Olga Carmona, Ester Moral, José Vicente Hervás, Yolanda Blanco, Nuria Sola-Valls, Nieves Tellez Lara, Lucía Forero, Luis Brieva
Format: Article
Language:English
Published: MDPI AG 2023-11-01
Series:Journal of Clinical Medicine
Subjects:
Multiple Sclerosis
COVID-19
SARS-CoV-2
DMT
seroprevalence
Online Access:https://www.mdpi.com/2077-0383/12/23/7243

Internet

https://www.mdpi.com/2077-0383/12/23/7243

Similar Items